# Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril

Study · id `cardio:ct-nct02654678` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02654678](<https://clinicaltrials.gov/study/NCT02654678>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02654678

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02654678. Allocation not applicable; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2018-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02654678, source copy `cardio:ctgov-nct02654678-2016-01-13`, retrieved 2026-10-26)
- Start date: 2016-03 (registry gives no type) (ClinicalTrials.gov record NCT02654678, source copy `cardio:ctgov-nct02654678-2016-01-13`, retrieved 2026-10-26)
- Primary completion: 2018-04 (anticipated) (ClinicalTrials.gov record NCT02654678, source copy `cardio:ctgov-nct02654678-2016-01-13`, retrieved 2026-10-26)
- Completion: 2018-04 (anticipated) (ClinicalTrials.gov record NCT02654678, source copy `cardio:ctgov-nct02654678-2016-01-13`, retrieved 2026-10-26)
- Countries: Austria; Hungary; Netherlands; Serbia; United Kingdom (ClinicalTrials.gov record NCT02654678, source copy `cardio:ctgov-nct02654678-2016-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02654678-2016-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril
- Acronym: LENA-WP10
- Condition: Heart Failure
- Condition: Dilated Cardiomyopathy
- Condition: Congenital Heart Disease
- Intervention (Drug): Enalapril Orodispersible Minitablet
- Lead sponsor: Ethicare GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)

## Provenance

Content hash: 830c9abe4f89725ff59205f9bd67caccbebee151e40c35d6f3f5dfc7514bdd4a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
